Back to Clinical Trials

Brief Title: CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

INTRODUCTION

  • Org Study ID: CBX-12-101
  • Secondary ID: N/A
  • NTC ID: NCT04902872
  • Sponsor: Cybrexa Therapeutics

BRIEF SUMMARY

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.

DETAILED DESCRIPTION

Phase 1 is the dose-escalation portion of the study in which the safety and tolerability of two dosing schedules of CBX-12 will be evaluated. Subjects in Part A will be treated with CBX-12 on a daily x 5 every 3 weeks schedule (treatment in Part A was discontinued in October 2021). Subjects in Phase 1 Part B will be treated with CBX-12 on a daily x 3 every 3 weeks schedule. Subjects in Phase 1 Part C will be treated with CBX-12 once weekly.

For all parts in Phase 1, after all subjects in a cohort have completed treatment through the DLT period or discontinued treatment due to a DLT, the SRC, composed of the Investigators who have enrolled subjects in the current cohort(s), the study Medical Monitor and ad hoc members (e.g., other Investigators, a statistician) as needed, will review all available safety data, including DLTs and all available PK data for that cohort and make dose-level recommendations.

Once the recommended phase 2 dose (RP2D) has been established in both Part B and Part C, Phase 2 expansion cohorts may open.

  • Overall Status
    Recruiting
  • Start Date
    May 3, 2021
  • Phase
    Phase 1, Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Phase 1: Incidence of treatment-emergent adverse events (TEAEs)

Primary Outcome 1 - Timeframe: Through the end of study, estimated as 6 months

Primary Outcome 2 - Measure: Phase 1: Recommended Phase 2 Dose for Daily x 3 every 3 weeks schedule of CBX-12

Primary Outcome 2 - Timeframe: 15 months

Primary Outcome 3 - Measure: Phase 1: Recommended Phase 2 Dose for Once Weekly schedule of CBX-12

Primary Outcome 3 - Timeframe: 15 months

Primary Outcome 4 - Measure: Phase 2: Overall response rate (ORR)

Primary Outcome 4 - Timeframe: Through the end of study, estimated as 6 months

CONDITION

  • Solid Tumor
  • Adult
  • Epithelial Ovarian Cancer
  • Small Cell Lung Carcinoma
  • Breast Cancer
  • Colorectal Cancer
  • Pancreas Cancer
  • Appendix Cancer
  • Non-small Cell Lung Cancer
  • Gastric Cancer
  • Esophagus Cancer
  • Urothelial Carcinoma
  • Sarcoma

ELIGIBILITY

Key Inclusion Criteria:
Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists. Subject's prior treatment should include all approved regimens that have demonstrated a survival advantage for the subject's disease, stage, and line of therapy.

- Has measurable disease per RECIST 1.1.

- An adequate tumor sample must be available from core needle biopsies obtained during the Screening Period and following the subject's most recent systemic therapy.

- Agrees to an on-treatment biopsy preferably of the same lesion from which the pre-CBX-12 treatment sample was obtained as long as the Investigator determines such biopsy can be performed with acceptable safety.
Exclusion Criteria:
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy less than or equal to 3 weeks prior to the first dose of CBX-12. The interval may be reduced to 2 weeks for bone only radiation therapy or investigational agents not expected to be associated with adverse events (AEs) after 2 weeks of last administration, with Medical Monitor approval.

- Small-molecule kinase inhibitors or hormonal agents less than or equal to 14 days prior to the first dose of CBX-12.

- Subjects who are currently receiving any other anti cancer or investigational agent(s).

- Clinically significant intercurrent disease.

- Subjects with primary central nervous system (CNS) tumors or clinically active CNS metastases or carcinomatous meningitis. Subjects with stable brain metastasis may be enrolled with Medical Monitor approval.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Chief Medical Officer

Role: Study Director

Affiliation: Cybrexa Therapeutics

Overall Contact

Name: Chief Medical Officer

Phone: 860-501-3027

Email: clinicalstudies@cybrexa.com

LOCATION

Facility Status Contact
Facility: Yale Cancer Center
New Haven, Connecticut 06511
United States
Status: Recruiting Contact: Contact
Ingrid Palma
203-833-1034
ingrid.palma@yale.edu
Facility: NEXT Oncology
Austin, Texas 78758
United States
Status: Recruiting Contact: Principal Investigator
Joseph Paul Eder, MD
210-580-9520
gchambers@nextoncology.com
Facility: MD Anderson Cancer Center
Houston, Texas 77030
United States
Status: Recruiting Contact: Contact
Glenda Chambers
737-618-5210
nklein@nextoncology.com
Facility: NEXT Oncology
San Antonio, Texas 78229
United States
Status: Recruiting Contact: Contact
Nicole Klein
713-302-9904
kaluna@mdanderson.org